IRIS
TROIANI, Teresa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.711
NA - Nord America 3.318
AS - Asia 798
OC - Oceania 13
SA - Sud America 13
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.865
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.270
IE - Irlanda 1.230
IT - Italia 767
GB - Regno Unito 369
UA - Ucraina 346
DE - Germania 339
SG - Singapore 297
CN - Cina 281
FR - Francia 235
SE - Svezia 118
GR - Grecia 106
FI - Finlandia 96
TR - Turchia 75
KR - Corea 54
CA - Canada 42
BE - Belgio 29
NL - Olanda 23
PK - Pakistan 22
VN - Vietnam 22
CZ - Repubblica Ceca 17
IN - India 15
ES - Italia 14
AU - Australia 7
IR - Iran 7
HK - Hong Kong 6
IL - Israele 6
MX - Messico 6
NZ - Nuova Zelanda 6
AT - Austria 5
BJ - Benin 5
BR - Brasile 4
CH - Svizzera 4
CO - Colombia 4
MK - Macedonia 4
JP - Giappone 3
BD - Bangladesh 2
CL - Cile 2
EU - Europa 2
GI - Gibilterra 2
HU - Ungheria 2
PE - Perù 2
RU - Federazione Russa 2
TH - Thailandia 2
TW - Taiwan 2
AR - Argentina 1
BW - Botswana 1
BY - Bielorussia 1
EG - Egitto 1
KG - Kirghizistan 1
LK - Sri Lanka 1
MA - Marocco 1
MY - Malesia 1
NG - Nigeria 1
PH - Filippine 1
PL - Polonia 1
RO - Romania 1
TN - Tunisia 1
Totale 7.865
Salva come PNG Salva come JPEG
Città #
Dublin 1.216
Chandler 669
Jacksonville 560
Singapore 195
Santa Clara 188
Princeton 162
New York 145
Bremen 138
Roxbury 129
Medford 121
Naples 121
Ann Arbor 120
Beijing 91
Caserta 75
Wilmington 72
Munich 61
Boardman 58
Cambridge 47
Nanjing 46
San Mateo 43
Des Moines 42
Woodbridge 38
Elora 34
Napoli 34
Seoul 34
Milan 31
Brussels 29
Los Angeles 29
Ashburn 27
Dong Ket 22
Houston 21
Mountain View 17
Brno 16
Rome 16
Amsterdam 15
Nanchang 15
Norwalk 15
Lappeenranta 13
Tianjin 12
Jinan 11
Düsseldorf 9
Shanghai 9
Bahawalpur 8
Castello di Brianza 8
Helsinki 8
Istanbul 8
Madrid 8
Redwood City 8
Cava Dei Tirreni 7
Kunming 7
Pozzuoli 7
Auburn Hills 6
Changchun 6
Giv‘atayim 6
Hangzhou 6
Rimini 6
Seattle 6
Shenyang 6
Taiyuan 6
Zhengzhou 6
Castellammare Di Stabia 5
Florence 5
Venice 5
Anantapur 4
Battipaglia 4
Bogotá 4
Changsha 4
Ercolano 4
Fairfield 4
Groningen 4
Hebei 4
Monte Di Procida 4
Nola 4
Sennori 4
Taizhou 4
Toronto 4
Vienna 4
Zurich 4
Acerra 3
Avellino 3
Brisbane 3
Chengdu 3
Chicago 3
Colle di Val d'Elsa 3
Delhi 3
Guangzhou 3
Hong Kong 3
Lanzhou 3
London 3
Matera 3
Menlo Park 3
Montecorvino Rovella 3
Mugnano di Napoli 3
Orange 3
Ottawa 3
Pellezzano 3
Pune 3
Redmond 3
São Paulo 3
Viareggio 3
Totale 5.010
Salva come PNG Salva come JPEG
Nome #
ONCOLOGIA MEDICA 148
Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells 104
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 103
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 95
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 87
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 87
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 81
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 80
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 77
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 77
Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass 74
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 72
TRASTUZUMAB RESISTANCE IN BREAST CANCER 72
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 70
Farmacogenomica e cancro colorettale 69
AXL is an oncotarget in human colorectal cancer 67
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 67
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 66
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 64
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 64
Antiangiogenic drugs in non small cell lung cancer treatment 63
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 63
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors 62
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer 62
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 62
Therapeutic integration of signal trasdution targeting agents an conventional anticancer treatments 61
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 61
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 61
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 60
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 60
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 59
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 59
Combination of anti-EGFR drugs and other molecular targeted agents as anti-cancer strategy 59
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 59
Beyond N staging in colorectal cancer: Current approaches and future perspectives 58
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model 58
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines 57
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRI-GOIM trial. 56
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 56
The potential diagnostic and predictive role of anaplastic lymphoma kinase (ALK) gene alterations in melanocytic tumors 56
Vandetaninb, a dual inhibitor of VEGFR and EGFR tyrosine kinase activity 55
Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC 55
Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab? 55
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial 55
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase 54
Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. 54
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases 54
Targeting EGFR in Pancreatic Cancer Treatment. 54
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 54
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy 53
MET ACTIVATION BY AUTOCRINE LOOP RESCUES COLON CANCER CELLS FROM SENSITIVITY TO EGFR INHIBITION 52
Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. 52
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 52
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. 51
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program 51
Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment 50
Erlotinib in cancer treatment 50
intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy 49
Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy 49
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case 49
It is finally time for adjuvant therapy in melanoma 49
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 49
Spectroscopic Characterization and Cytotoxicity Assessment towards Human Colon Cancer Cell Lines of Acylated Cycloartane Glycosides from Astragalus boeticus L. 49
Macrophage migration inhibitory factor is a molecular determinant of the anti-EGFR monoclonal antibody cetuximab resistance in human colorectal cancer cells 49
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 49
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 49
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa) 48
MEK inhibitor as a single agent and in combination with everolimus or sorafenib in a panel of colorectal cancer cell lines: implication for multitargeted approach 47
Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. 47
PHASE I/II STUDY OF FOLFIRI PLUS THE MEK1/2 INHIBITOR PIMASERTIB (MSC1936369B) AS SECOND-LINE TREATMENT FOR KRAS MUTATED METASTATIC COLORECTAL CANCER 47
Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis 47
Cytologic diagnosis of metastatic melanoma by FNA: A practical review 47
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 47
Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer 46
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. 46
External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life 46
Metformin in lung cancer: rationale for a combination therapy 46
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 46
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines 46
OPTIMIZING THERAPEUTIC COMBINATIONS OF A SELECTIVE MEK 1/2 INHIBITOR (PIMASERTIB) WITH PI3K/ MTOR INHIBITORS OR WITH MULTI-TARGETED KINASE INHIBITORS IN PIMASERTIB-RESISTANT HUMAN LUNG AND COLORECTAL CANCER CELLS 46
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. 46
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. 46
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 46
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 46
Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity 45
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 45
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 45
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 45
Resistance mechanisms of tumour cells to EGFR inhibitors 44
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 44
Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells 42
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 42
PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples 42
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 42
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer 41
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 41
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): From clinical trials to clinical practice 41
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 41
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 40
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 40
Totale 5.674
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.404
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.404
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020563 0 0 0 0 95 19 138 63 94 76 63 15
2020/2021958 82 18 102 52 141 25 119 96 29 115 124 55
2021/20221.163 57 26 27 25 340 25 37 35 57 90 120 324
2022/20232.567 255 56 46 237 283 233 10 158 1.150 14 71 54
2023/20241.111 102 49 40 67 329 171 33 33 21 16 86 164
2024/2025677 61 93 47 139 337 0 0 0 0 0 0 0
Totale 8.303